

T Cell-Replete Haploidentical Transplantation with Post-Transplant
Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous
Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host
Disease in HLA-Identical Related Donors

Biology of Blood and Marrow Transplantation

24, 627-632

DOI: [10.1016/j.bbmt.2017.11.030](https://doi.org/10.1016/j.bbmt.2017.11.030)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Outcomes of Advanced Hodgkin Lymphoma after Umbilical Cord Blood Transplantation: A Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2265-2270.	2.0	10
2	Discussion on the indication of allogeneic stem cell transplantation for advanced cutaneous T cell lymphomas. <i>International Journal of Hematology</i> , 2019, 110, 406-410.	0.7	4
3	T-Cell Replete Haploidentical Transplantation. , 2019, , 99-123.		1
4	Haploidentical Stem Cell Transplantation With Post-Transplantation Cyclophosphamide for Aggressive Lymphomas: How Far Have We Come and Where Are We Going?. <i>World Journal of Oncology</i> , 2019, 10, 1-9.	0.6	4
5	Regulatory T cells in allogeneic hematopoietic stem cell transplantation: From the lab to the clinic. <i>Cellular Immunology</i> , 2019, 346, 103991.	1.4	7
6	Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. <i>Journal of Hematology and Oncology</i> , 2019, 12, 108.	6.9	51
7	Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts. <i>American Journal of Hematology</i> , 2019, 94, 512-521.	2.0	51
8	Peripheral Blood Stem Cells versus Bone Marrow for T Cellâ€“Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1810-1817.	2.0	15
9	Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamideâ€“Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1859-1868.	2.0	58
10	Granulocyte Colony-Stimulating Factor-Primed Unmanipulated Haploidentical Blood and Marrow Transplantation. <i>Frontiers in Immunology</i> , 2019, 10, 2516.	2.2	36
11	Recent progress in haploidentical transplantation: is this the optimal choice for alternative donor transplantation?. <i>Current Opinion in Hematology</i> , 2019, 26, 406-412.	1.2	5
12	Is human leukocyte antigen-matched sibling donor transplant always better than haploidentical allograft?. <i>Seminars in Hematology</i> , 2019, 56, 201-208.	1.8	10
13	Allogeneic hematopoietic stem cell transplantation in r/r Hodgkin lymphoma after treatment with checkpoint inhibitors: Feasibility and safety. <i>European Journal of Haematology</i> , 2019, 102, 150-156.	1.1	20
14	Haploidentical stem cell transplantation for patients with lymphoma: a position statement from the Lymphoma Working Party-European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 317-324.	1.3	13
15	Allogeneic stem cell transplantation improves survival in relapsed Hodgkin lymphoma patients achieving complete remission after salvage treatment. <i>Bone Marrow Transplantation</i> , 2020, 55, 117-125.	1.3	12
17	Haploidentical Stem Cell Transplantation in Lymphomasâ€“Expectations and Pitfalls. <i>Journal of Clinical Medicine</i> , 2020, 9, 3589.	1.0	6
18	Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study. <i>International Journal of Hematology</i> , 2020, 112, 674-689.	0.7	19
19	Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma: an analysis of the Lymphoma Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2020, 55, 2170-2179.	1.3	8

#	ARTICLE	IF	CITATIONS
20	Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 2020, 99, 1377-1387.	0.8	15
21	Haploidentical versus identical sibling transplant for high-risk pediatric AML: A multicenter study. <i>Cancer Communications</i> , 2020, 40, 93-104.	3.7	20
22	Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: A Retrospective Cohort Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1679-1688.	2.0	25
23	Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR. <i>Journal of Clinical Oncology</i> , 2020, 38, 1518-1526.	0.8	34
24	Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2020, 190, 573-582.	1.2	19
25	Immunosenescent characteristics of T cells in young patients following haploidentical haematopoietic stem cell transplantation from parental donors. <i>Clinical and Translational Immunology</i> , 2020, 9, e1124.	1.7	8
26	Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study. <i>Journal of Hematology and Oncology</i> , 2020, 13, 27.	6.9	48
27	Different Effects of Pre-transplantation Measurable Residual Disease on Outcomes According to Transplant Modality in Patients With Philadelphia Chromosome Positive ALL. <i>Frontiers in Oncology</i> , 2020, 10, 320.	1.3	17
28	Allogeneic hematopoietic stem cell transplantation from a 2-HLA-haplotype-mismatched family donor for posttransplant relapse: a prospective phase I/II study. <i>Bone Marrow Transplantation</i> , 2021, 56, 70-83.	1.3	3
29	Can we cure refractory Hodgkin's lymphoma with transplantation?. <i>Bone Marrow Transplantation</i> , 2021, 56, 278-281.	1.3	2
30	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <i>Leukemia</i> , 2021, 35, 2672-2683.	3.3	45
31	Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1172-1185.	4.8	55
33	Effect of donor characteristics on T cell-replete haploidentical stem cell transplantation over the last 10 years at a single institution. <i>British Journal of Haematology</i> , 2022, 196, 1225-1238.	1.2	7
34	How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond. <i>Blood</i> , 2023, 141, 49-59.	0.6	26
41	Haploidentical donor the donor of choice in the treatment of relapse Hodgkin's lymphoma. <i>Medicinski Pregled</i> , 2022, 75, 54-56.	0.1	0
42	Outcomes after allogeneic hematopoietic stem cell transplantation for adults with primary mediastinal B cell lymphoma: a SFGM-TC and LYSA study. <i>Acta Oncologica</i> , 2022, 61, 1332-1338.	0.8	1
43	Haematopoietic stem-cell transplantation in China in the era of targeted therapies: current advances, challenges, and future directions. <i>Lancet Haematology</i> , 2022, 9, e919-e929.	2.2	20
45	Stem Cell Transplant for Hodgkin Lymphoma. , 2023, , 259-282.		0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------